Cooperation SeekingCreative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced ado-trastuzumab emtansine. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
Trastuzumab Emtansine is a HER2 antibody drug conjugate. The antibody part is humanized anti-HER2 IgG1 trastuzumab, and the drug part is DM1, which is a maytansin derivative that inhibits microtubules. Emtansine is a generic name for 4- [N-maleimidomethyl] cyclohexane-1-carboxylic acid ester (MCC) covalently linking linker and DM1, which is produced through chemical synthesis. Trastuzumab Emtansine binds to subdomain IV of the HER2 receptor and enters the cell through receptor-mediated endocytosis. DM1 binds to tubulin in microtubules and inhibits microtubule function, resulting in cell arrest and apoptosis. Similarly, similar to trastuzumab, in vitro antibody-dependent cytotoxicity and inhibition of HER2 receptor signaling are mediated by the antibody portion of trastuzumab emtansine.
It is suitable for treating early HER2-positive early breast cancer or metastatic breast cancer that substantially overexpresses HER2. Approved for gastric cancer, metastatic gastroesophageal junction adenocarcinoma, and metastatic adenocarcinoma of the gastro-esophageal junction, provided that these cancers overexpress HER2.
All products and services are for Research Use Only. Do Not use in humans.
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.